SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 110 filers reported holding SUTRO BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $104,159 | -22.6% | 30,017 | +3.7% | 0.00% | 0.0% |
Q2 2023 | $134,618 | +12.0% | 28,950 | +11.3% | 0.00% | 0.0% |
Q1 2023 | $120,203 | -41.7% | 26,018 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $206,040 | +59.7% | 25,500 | +9.8% | 0.00% | 0.0% |
Q3 2022 | $129,000 | +20.6% | 23,227 | +12.7% | 0.00% | 0.0% |
Q2 2022 | $107,000 | -39.5% | 20,602 | -4.3% | 0.00% | 0.0% |
Q1 2022 | $177,000 | -48.4% | 21,527 | -6.6% | 0.00% | -50.0% |
Q4 2021 | $343,000 | -23.4% | 23,042 | -2.9% | 0.00% | 0.0% |
Q3 2021 | $448,000 | -0.9% | 23,732 | -2.3% | 0.00% | 0.0% |
Q2 2021 | $452,000 | +4.9% | 24,296 | +28.3% | 0.00% | 0.0% |
Q1 2021 | $431,000 | +22.4% | 18,943 | +16.9% | 0.00% | +100.0% |
Q4 2020 | $352,000 | +125.6% | 16,210 | +4.6% | 0.00% | 0.0% |
Q3 2020 | $156,000 | +95.0% | 15,498 | +51.1% | 0.00% | – |
Q2 2020 | $80,000 | +21.2% | 10,260 | +59.3% | 0.00% | – |
Q1 2020 | $66,000 | -12.0% | 6,440 | -5.5% | 0.00% | – |
Q4 2019 | $75,000 | +21.0% | 6,814 | -0.8% | 0.00% | – |
Q3 2019 | $62,000 | -21.5% | 6,870 | -0.7% | 0.00% | – |
Q2 2019 | $79,000 | +71.7% | 6,918 | +69.7% | 0.00% | – |
Q1 2019 | $46,000 | +21.1% | 4,076 | -3.2% | 0.00% | – |
Q4 2018 | $38,000 | – | 4,209 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |